Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1809 results
October 2018
-
Story Discovery
On being and becoming a data science company
A conversation with Novartis Chief Digital Officer Bertrand Bodson
-
Media Release
Alcon to develop SMART Suite digital health platform for cataract surgery
SMART Suite by Alcon will drive innovation in ophthalmology delivering personalized and seamless end-to-end care for cataract patients As an open, secure cloud-enabled ecosystem, SMART… -
Media Release
Novartis announces Lancet publication of pioneering study in migraine prevention showing efficacy of Aimovig® where other treatments have failed
The LIBERTY trial is the first study of a CGRP-targeted therapy in a patient population where multiple preventive treatments had previously failed Patients treated with Aimovig, reported… -
Media Release
Novartis COMBI-AD study of Tafinlar® + Mekinist® continues to demonstrate relapse free survival benefit in patients with BRAF V600-mutant stage III melanoma
Extended follow up results confirm leading BRAF/MEK inhibitor combination Tafinlar + Mekinist continues to show relapse free survival benefit Cure rate modeling which estimates fraction of… -
Media Release
Novartis investigational BYL719 (alpelisib) plus fulvestrant nearly doubles median PFS in patients with PIK3CA mutated HR+/HER2- advanced breast cancer compared to fulvestrant alone
In SOLAR-1 trial, BYL719 plus fulvestrant significantly improved PFS and ORR in these patients, following progression on or after an aromatase inhibitor with or without a CDK4/6 inhibitor, vs.… -
Media Release
Novartis phase II GEOMETRY mono-1 trial of investigational medicine capmatinib (INC280) shows positive results in patients with MET mutated advanced NSCLC
Phase II study efficacy data showed overall response rate of 72.0% and 39.1%, respectively, in treatment-naive and previously treated patients with advanced MET exon-14 skipping mutated non-small… -
Media Release
Novartis announces presentation of new Lutathera® NETTER-1 data at ESMO demonstrating significant improvement in PFS regardless of baseline liver tumor burden
Lutathera treatment was associated with an ~80% reduction in the estimated risk of tumor progression or death vs comparator, regardless of baseline liver tumor burden[1] Lutathera treatment was… -
Key Release
Novartis announces planned acquisition of Endocyte to expand expertise in radiopharmaceuticals and build on commitment to transformational therapeutic platforms
Novartis to acquire Endocyte to accelerate development of innovative radioligand technology for treating cancer Acquisition would add 177Lu-PSMA-617, a potential first-in-class… -
Key Release
Novartis erzielt im dritten Quartal starkes Wachstum und treibt Innovationen wie fortschrittliche Therapieplattformen voran, um das zukünftige Wachstum zu beschleunigen
Der Nettoumsatz steigt um 6% (kWk[1], +3% USD), vor allem dank folgender Beiträge: Cosentyx erzielt mit starken Volumenzuwächsen in allen Indikationen einen Umsatz von USD 750 Millionen (+37% kWk… -
Key Release
Novartis a enregistré, au troisième trimestre, une forte croissance et fait preuve d'une innovation dynamique, incluant des plateformes thérapeutiques avancées pour soutenir la croissance future
Hausse du chiffre d'affaires net de 6% (tcc[1], +3% USD), stimulée principalement par: Cosentyx, qui a progressé à USD 750 millions (+37% tcc) grâce à une forte croissance en volume dans toutes… -
Key Release
Novartis delivered strong growth and innovation during the third quarter, including progressing advanced therapy platforms to drive future growth
Net sales grew 6% (cc[1], +3% USD) mainly driven by: Cosentyx grew to USD 750 million (+37% cc) with strong volume growth across indications Entresto more than doubled to USD 271 million (+113… -
Media Release
Novartis 5-year data in psoriatic arthritis and ankylosing spondylitis reinforces Cosentyx® leadership in spondyloarthritis
Data from the MEASURE 1 and FUTURE 1 studies show rapid and long-lasting sustained improvement in the signs and symptoms of ankylosing spondylitis (AS) and psoriatic arthritis (PsA)[1],[2] …